Fluvoxamine and Fentanyl: Interaction Details
- Fentanyl
- AbstralActiqFentora +3 more
- Fluvoxamine
- LuvoxLuvox CR
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fluvoxamine and Fentanyl interaction:
Fentanyl
- Abstral
- Actiq
- Fentora
- Onsolis
- Subsys
- Ionsys
Fluvoxamine
- Luvox
- Luvox CR
What Happens When You Take Fluvoxamine With Fentanyl
What can happen when they are taken together (rated Major)
Increased fentaNYL exposure and an increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Using fentaNYL together with a that also has activity may result in serotonin syndrome, and it can raise fentaNYL exposure, which in turn may heighten or extend adverse events. symptoms usually appear within several hours to a few days after the drugs are started together, though they can emerge later.
When the combination cannot be avoided, a lower fentaNYL dose should be considered until drug effects stabilize, and patients should be checked often for and . Once a CYP3A4 inhibitor is stopped, its effect wanes and fentaNYL exposure falls, which can lead to diminished or to a withdrawal syndrome in patients who have become physically dependent on fentaNYL.
If the CYP3A4 inhibitor is discontinued, raising the fentaNYL dose should be considered until stable drug effects are reached, and patients should be monitored for signs of opioid withdrawal.234 Patients should also be watched for symptoms of serotonin syndrome, which can be life-threatening. Should it occur, the offending agents must be stopped, and supportive care along with any other needed therapy should be given.1
The Fluvoxamine and Fentanyl Interaction, Explained
Fluvoxamine can make fentanyl stronger and last longer in your body, and the two together can raise too high. Fluvoxamine slows down an enzyme () that helps clear fentanyl, so more fentanyl stays in your system. That can mean more drowsiness and slowed breathing. Both drugs also affect serotonin, so there is a risk of , which can cause agitation, sweating, shaking, fast heartbeat, fever, or muscle stiffness. It is rare but can be serious.
Do not stop or change either medicine on your own. Your care team can manage this by adjusting your fentanyl dose and checking on you more often. Call your doctor or pharmacist right away if you notice these symptoms.
Mechanism: Fluvoxamine inhibits (fentanyl's main pathway), increasing fentanyl exposure, and both agents add activity. Fentanyl is active itself (not a ), so increases effect.
- Effects: Increased or prolonged effects (, ) and risk of , which can be life-threatening.
- Onset: symptoms typically within hours to a few days, but may occur later.
- Evidence: Established; severity major.
- Management: If is necessary, consider fentanyl dose reduction until stable effects are achieved, and monitor frequently for respiratory depression, sedation, and serotonin toxicity. If fluvoxamine is stopped, fentanyl exposure falls; consider increasing the dose to effect and monitor for opioid withdrawal. If serotonin syndrome develops, discontinue the offending agents and give supportive care.
See the 11 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fluvoxamine and Fentanyl Interact
The likely mechanism
of -mediated of fentaNYL;
How to Manage the Fluvoxamine and Fentanyl Interaction
Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your care team may lower your fentanyl dose until your response is stable and may monitor you more closely for sleepiness and slowed breathing.
- Tell your pharmacist or prescriber about all medicines you take, including any change to fluvoxamine.
- If fluvoxamine is stopped, fentanyl levels can drop, so your team may need to adjust your fentanyl dose again and watch for withdrawal symptoms or poor pain control.
- Seek help promptly for agitation, sweating, tremor, fever, fast heartbeat, muscle stiffness, or very slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fluvoxamine or Fentanyl need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
9 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
The serotonin syndrome
presents with neuromuscular abnormalities (eg, hyperreflexia, tremor, muscle rigidity, clonus, peripheral hypertonicity, shivering), autonomic hyperactivity (eg, , mydriasis, diaphoresis, audible bowel sounds, diarrhea), and altered mental status (eg, agitation, delirium). The condition can be life-threatening.1
-
Report 2 · Study title
Case scenario: opioid association with serotonin syndrome: implications to the practitioners
A case report describes -associated in a 58-year-old man with chronic back pain. He had been stable on treatment for pain and depression, with a regimen of transdermal fentaNYL 75 mcg/hr patches, oxyCODONE 5 mg/acetaminophen 325 mg twice daily, celecoxib 200 mg twice daily, citalopram 40 mg once daily, and mirtazapine 50 mg at night.
He was also taking doxazosin 4 mg daily and zolpidem 12.5 mg as needed for insomnia. Because he reported inadequate pain control, the fentaNYL patch schedule was changed from replacement every 3 days to every 2 days.
About 1 week after this fentaNYL increase, he reported anxiety, tremulousness, fever, and sweating. CloNIDine 0.2 mg every 4 hours was started, with no improvement in symptoms.
Symptoms persisted, and the next day haloperidol and LORazepam were given for anxiety and agitation. He stopped his fentaNYL patch and, 2 days later, presented to the emergency room with opiate withdrawal.
He was then diagnosed with serotonin syndrome, even though the fentaNYL patch had been discontinued for 30 hours. Haloperidol, fentaNYL, oxyCODONE/acetaminophen, citalopram, and mirtazapine were stopped immediately, and symptoms resolved completely by the following day. Morphine sulfate was prescribed in place of fentaNYL, and citalopram and mirtazapine were restarted, with no recurrence of symptoms at follow-up.5
-
Report 3 · Study title
Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy
associated with fentaNYL use during esophagogastroduodenoscopy was reported in a 39-year-old woman who was also taking sertraline 100 mg daily as an outpatient. She initially presented with hematemesis and had a history of alcoholic cirrhosis.
Before the esophagogastroduodenoscopy, an octreotide and pantoprazole drip was started, and 2 doses of fentaNYL 50 micrograms and 2 doses of midazolam 1 mg were given. After the procedure she became somnolent and markedly rigid in all four extremities, and vecuronium and etomidate were administered for immediate intubation.
The rigidity progressed, accompanied by diffuse diaphoresis, horizontal roving eye movements, and a fever of 105 degrees F. Because of the possibility of seizure activity, LORazepam 2 mg IV was given without improvement, and a propofol drip was begun for continued during intubation.
A CPK of 2800 units/L and an ammonia level of 340 micromols/L indicated . A CT scan of the brain ruled out an acute intracranial process, and the neurology team diagnosed serotonin syndrome secondary to an interaction between fentaNYL and sertraline.
Propofol was continued for sedation, and supportive treatment consisted of a cooling blanket and cyproheptadine. After 3 days her temperature and CPK normalized, and she was later extubated without further complications.6
-
Report 4 · Study title
Serotonin syndrome precipitated by fentanyl during procedural sedation
after IV fentaNYL during surgical procedures was reported in 2 patients who were also taking (sertraline and escitalopram). The first patient received IV fentaNYL (50 micrograms), midazolam (2 mg), and 2 doses of propofol (60 mg and 40 mg) at an outpatient surgery center before a carpal tunnel release.
Postoperatively she began shivering and grew increasingly agitated, and was transferred to the emergency department. On presentation she was combative, diaphoretic, confused, unable to follow commands, tachycardic, and hypertensive, with hyperreflexia and ankle clonus.
Creatinine kinase rose from baseline to 613 units/L on hospital day 2. The toxicology service treated her with escalating doses of without improvement.
She was then intubated and sedated with a continuous propofol infusion. She was extubated after 2 days, all symptoms had resolved by day 3, and she was discharged home.
The second patient, a 59-year-old woman, was admitted for an omentectomy and received IV fentaNYL 250 micrograms, etomidate, vecuronium, morphine, and cephazolin. After extubation she became hypoxic and acidotic, and was reintubated and transferred to the ICU.
On postoperative day 1 she was extubated, and later became tachycardic and unable to follow commands. Examination showed agitation, diaphoresis, patellar hyperreflexia, and bilateral ankle clonus of 3 to 4 beats.
Laboratory evaluation was notable for a peak creatine kinase of 1161 units/L on postoperative day 2. She was treated with LORazepam and cyproheptadine, and symptoms resolved after 3 days.7
-
Report 5 · Study title
Serotonin toxicity caused by an interaction between fentanyl and paroxetine
A case of postoperative after fentaNYL use for general anesthesia and postoperative analgesia was reported in a 60-year-old woman who was also receiving PARoxetine. Her outpatient medications were limited to PARoxetine and thyroxine, for depression and hypothyroidism.
She was admitted for extensive resection of a recurrent left chest wall myxofibrosarcoma and received propofol and 200 micrograms (mcg) of fentaNYL for of anesthesia. She also received an additional 800 mcg of fentaNYL intraoperatively (intermittent 50 mcg boluses), followed by a fentaNYL infusion (100 to 200 mcg/hr) for postoperative and analgesia (2545 mcg of fentanyl over 36 hours).
The infusion was continued for 36 hours postoperatively, at which point neurological examination revealed intermittent agitation, bilateral hypertonia and hyperreflexia, and bilateral inducible ankle clonus. Symptoms were more severe in the lower limbs and on the right side of the body.
A CT scan of the brain was unremarkable, and all other findings, including thyroid function tests, were within normal limits except for elevated blood pressure (180/90 mmHg), which resolved spontaneously 24 hours after the procedure. fentaNYL was discontinued, and 24 hours later neurological symptoms had improved markedly, with complete recovery by postoperative day 4. She was ultimately discharged home without further complications.8
-
Report 6 · Study title
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life
Twelve healthy volunteers received either placebo or oral ritonavir 3 times daily for 3 days, and a dose of fentaNYL 5 mcg/kg IV was given after the second ritonavir dose on day 2. Naloxone was given before and together with the fentaNYL dose to prevent fentaNYL's sedative and respiratory depressant effects.
One subject withdrew from the study before receiving fentaNYL. In the 11 remaining participants, ritonavir reduced the plasma of fentaNYL by 67% (from 15.6 to 5.2 mL/min/kg).
Compared with placebo, the of fentaNYL rose from 9.4 hours to 20.1 hours after ritonavir, and the area under the concentration-time curve () rose by 174% (from 6.6 to 18.1 ng/mL/hr). Ritonavir is considered likely to affect the elimination of transdermally administered fentaNYL in a similar way.9
-
Report 7 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, of fluconazole with a single IV dose of fentaNYL reduced the mean plasma of fentaNYL by 16%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the final fluconazole dose on day 2 (400 mg orally once daily on day 1, then 200 mg orally once daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects completed the study.
In the fluconazole phase, mean plasma clearance was 16% lower than in the control phase (range, -34% to 53%; p less than 0.05). The increase in fentaNYL was not significant (fluconazole phase, 7.7 +/- 2.3 nanograms (ng) x hr/mL vs control phase 6.1 +/- 1.1 ng x hr/mL), but the inactive norfentanyl decreased notably (fluconazole phase, 0.8 +/- 0.7 ng x hr/mL vs control phase, 1.8 +/- 1.1 ng x hr/mL), and the ratio of norfentanyl AUC to fentaNYL AUC was significantly lower in the fluconazole phase (AUC ratio, 0.1 +/- 0.1 vs 0.3 +/- 0.2).
Mean of fentaNYL did not differ between phases. The change in clearance appeared to result from of -mediated N-dealkylation of fentaNYL to norfentanyl.10
-
Report 8 · Study title
Possible fluconazole-fentanyl interaction-a case report
A 46-year-old man receiving transdermal fentaNYL died after concurrent treatment with fluconazole. He had oral pain from radiation therapy for tonsillar cancer and was treated with a fentaNYL 100 mcg/hr transdermal patch.
Over the next 1.5 months the fentaNYL dose was raised to 150 mcg/hr. medications were morphine 10 mg orally once daily, diclofenac 50 mg orally 3 times daily, paracetamol 1000 mg orally 3 times daily, oxazepam 15 mg orally twice daily, zolpidem 5 mg orally nightly, nystatin (100,000 international units/mL) 4 times daily, metoclopramide 20 mg rectally 3 times daily, lidocaine oral spray, and lactulose.
Two weeks after the increase to fentaNYL 150 mcg/hr, he had a percutaneous gastrostomy because of worsening dysphagia. Eight days later he developed an oral fungal infection and was started on oral fluconazole 50 mg/day.
Three days after that, he died in his sleep. Forensic analysis found a toxic concentration of fentaNYL (0.017 mcg/g), high concentrations of fluconazole (2.4 mcg/g), lidocaine (1.6 mcg/g), and metoclopramide (0.15 mcg/g), and a therapeutic concentration of zolpidem.
No ethanol or drugs of abuse were detected. The only pathological autopsy findings were pulmonary congestion and brain edema. There was no sign of intentional overdose, and the coroner concluded that the cause of death was and circulatory failure from fentaNYL intoxication.11
-
Report 9 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, of voriconazole with a single IV dose of fentaNYL raised the mean of fentaNYL 1.4-fold and lowered the mean plasma by 23%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the final voriconazole dose on day 2 (400 mg orally twice daily on day 1, then 200 mg orally twice daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects completed the study.
In the voriconazole phase, the mean AUC (0 to infinity) of fentaNYL was 1.4-fold higher (range, 0.81- to 2.04-fold) and mean plasma clearance was 23% lower (range -22% to 48%) than in the control phase. Notably, the mean fentaNYL at 12 hr in the voriconazole phase matched the concentration at 6 hr in the control phase.
Mean of fentaNYL again did not differ between phases. Nausea and vomiting were reported in 4 subjects during the voriconazole phase and 2 subjects during the control phase. No additional naloxone doses were needed, and no other adverse events were reported.10
Fluvoxamine and Fentanyl: Common Questions
How serious is the Fluvoxamine and Fentanyl interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fluvoxamine and Fentanyl interaction managed?
Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your care team may lower your fentanyl dose until your response is stable and may monitor you more closely for sleepiness and slowed breathing. Tell your pharmacist or prescriber about all medicines you take, including any change to fluvoxamine. If fluvoxamine is stopped, fentanyl levels can drop, so your… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Fluvoxamine and Fentanyl Interaction
Ask in your own words about taking Fluvoxamine and Fentanyl together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (11)
- Boyer EW & Shannon M: The serotonin syndrome. N Eng J Med 2005; 352(11):1112-1120. PubMed
- Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Rising Pharma Holdings, Inc. (per FDA), East Brunswick, NJ, 2025. DailyMed
- Product Information: ACTIQ® oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2025. DailyMed
- Product Information: FENTORA® buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2025.
- Rastogi R, Swarm RA, & Patel TA: Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology 2011; 115(6):1291-1298. PubMed
- Alkhatib AA, Peterson KA, & Tuteja AK: Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. Dig Dis Sci 2010; 55(1):215-216. DOI
- Kirschner R & Donovan JW: Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med 2010; 38(4):477-480. PubMed
- Rang ST, Field J, & Irving C: Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth 2008; 55(8):521-525. PubMed
- Olkkola KT, Palkama VJ, & Neuvonen PJ: Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685. PubMed
- Saari TI, Laine K, Neuvonen M, et al: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64(1):25-30. PubMed
- Hallberg P, Marten L, & Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62(6):491-492. PubMed
Other Serious Interactions of Fluvoxamine and Fentanyl
Also serious with Fentanyl
- IsocarboxazidContraindicated
- LevoketoconazoleContraindicated
- NaltrexoneContraindicated
- PhenelzineContraindicated
Also serious with Fluvoxamine
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Fentanyl
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- + 222 more
With Fluvoxamine
- Activated CharcoalMajor
- LithiumMajor
- CaffeineModerate
- Green TeaModerate
- Black PepperModerate
- GrapeModerate
- GinkgoModerate
- MelatoninModerate
- + 187 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.